The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Subscribe To Our Newsletter & Stay Updated
